摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-2-(3-bromo-5-nitro-4-pyridinyl)-N,N-dimethylethenamine | 1258875-12-5

中文名称
——
中文别名
——
英文名称
(E)-2-(3-bromo-5-nitro-4-pyridinyl)-N,N-dimethylethenamine
英文别名
2-(3-Bromo-5-nitropyridin-4-yl)-N,N-dimethylethyleneamine;2-(3-bromo-5-nitropyridin-4-yl)-N,N-dimethylethylenamine;2-(3-Bromo-5-nitro-4-pyridinyl)-N,N-dimethylethenamine;(E)-2-(3-bromo-5-nitropyridin-4-yl)-N,N-dimethylethenamine
(E)-2-(3-bromo-5-nitro-4-pyridinyl)-N,N-dimethylethenamine化学式
CAS
1258875-12-5
化学式
C9H10BrN3O2
mdl
——
分子量
272.101
InChiKey
WWOCIGHHNAXTRI-ONEGZZNKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    363.4±42.0 °C(Predicted)
  • 密度:
    1.551±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    62
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
    申请人:McAlpine James Indrawan
    公开号:US20050090529A1
    公开(公告)日:2005-04-28
    3,5 disubstituted indazole compounds with substituted nitrogen bearing 5-membered heterocycles in the 3-position that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating CDK dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    描述了在3-位置带有取代氮的5-成员杂环的3,5-二取代吲唑化合物,这些化合物调节和/或抑制细胞增殖,如蛋白激酶活性。这些化合物和含有它们的药物组合物能够调节和/或抑制介导CDK依赖性疾病的不需要的细胞增殖。该发明还涉及含有这些化合物的药物组合物的治疗或预防用途,以及通过给予这些化合物的有效量来治疗癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态,如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。
  • [EN] COMPOUNDS<br/>[FR] COMPOSÉS
    申请人:GLAXO GROUP LTD
    公开号:WO2010145201A1
    公开(公告)日:2010-12-23
    The present invention discloses novel compounds having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
    本发明公开了具有药理活性的新化合物,其制备方法,含有它们的药物组合物以及它们在治疗各种疾病中的用途。
  • Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors
    申请人:D'Orchymont Hugues
    公开号:US20060004000A1
    公开(公告)日:2006-01-05
    Compound corresponding to general formula (I): in which, R 1 represents a hydrogen or halogen atom, an NH 2 , NHR 2 , NHCOR 2 , NO 2 , CN, CH 2 NH 2 and CH 2 NHR 2 ; or alternatively R 1 represents an optionally substituted phenyl or an optionally substituted heteroaromatic group; Ar represents an optionally substituted phenyl group or an optionally substituted heteroaromatic group; n represents 0, 1, 2 or 3; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate. Application in therapy.
    通用公式(I)对应的化合物:其中,R1代表氢原子或卤素原子,NH2,NHR2,NHCOR2,NO2,CN,CH2NH2和CH2NHR2;或者R1代表可选择取代的苯基或可选择取代的杂环芳基;Ar代表可选择取代的苯基或可选择取代的杂环芳基;n表示0、1、2或3;以碱、与酸的加合盐、水合物或溶剂化合物的形式。在治疗中的应用。
  • INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA
    申请人:D'ORCHYMONT Hugues
    公开号:US20070185187A1
    公开(公告)日:2007-08-09
    The invention relates to methods of treating or preventing malaria which comprises administering to a patient in need thereof, an effective amount of a 1H-indazole-3-carboxamide derivative of general formula (I), in the form of a base or of an addition salt with an acid, or in the form of a hydrate or of a solvate of said base or acid addition salt.
    该发明涉及治疗或预防疟疾的方法,包括向需要的患者施用一种通式(I)的1H-吲唑-3-羧酰胺衍生物的有效量,其为碱式或与酸形成的加合盐的形式,或为所述碱式或酸性加合盐的水合物或溶剂化合物的形式。
  • PROKOPOV A. A.; YAXONTOV L. N., XIMIYA GETEROTSIKL. SOEDIN., 1979, HO 1, 86-88
    作者:PROKOPOV A. A.、 YAXONTOV L. N.
    DOI:——
    日期:——
查看更多